Drug Profile
Lopinavir/ritonavir sprinkle formulation - Cipla
Alternative Names: Lopimune Sprinkles; Lopinavir/ritonavir mini-melt tablets formulation; Lopinavir/ritonavir oral pellets; Ritonavir/lopinavirLatest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator Cipla
- Developer Cipla; Drugs for Neglected Diseases Initiative Foundation
- Class Amides; Antiretrovirals; Carbamates; Pyrimidinones; Small molecules; Thiazoles
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered HIV infections
- Phase III HIV-1 infections
Most Recent Events
- 30 Nov 2022 No development reported - Phase-III for HIV-1 infections (In children) in Tanzania (PO) (DNDi pipeline, November 2022)
- 30 Nov 2022 No development reported - Phase-III for HIV-1 infections (In children) in Uganda (PO) (DNDi pipeline, November 2022)
- 12 Feb 2022 Efficacy and adverse events data from the phase III LIVING trial in HIV infections presented at the 29th Conference on Retroviruses and Opportunistic Infections